吡格列酮对心血管病的防治作用被引量：3

下载PDF

导出

摘要心血管病（CVD）如高血压、动脉粥样硬化、心肌梗死、猝死等是危害人类健康的主要疾病。广泛用于2型糖尿病患肯治疗的吡格列酮为人工合成型过氧化物酶体增殖物激活受体γ（PPAR7）的高亲和性配体激活剂。相比其他的PPARγ激动剂如曲格列酮有严重肝脏毒性，罗格列酮长期服用可增加心绞痛或心肌梗死风险。有研究表明，毗格列酮除了降血糖和改善胰岛素敏感性作用外，还显示出多方面的心血管保护作用，安全性和耐受性较高，可降低心血管事件的发生率和病死率。

作者蔡辉董晓蕾赵智明李蓉

机构地区南京军区南京总医院中西医结合科

出处《中华老年心脑血管病杂志》 CAS 北大核心 2011年第10期946-948,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

关键词心血管疾病高血压动脉粥样硬化心肌梗死 PPARY 抗高血压药降血糖药

分类号 R54 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献28

1Petrazzi L,Grassi D, Polidoro L, et al. Cardiovascular risk and cardiometabolic protection: role of glitazones. J Nephrol,2008,21:826-835. 被引量：1
2l.incoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes melli tus:a meta analysis of randomized trials. JAMA, 2007,298: 1180- 1188. 被引量：1
3Betteridge DJ, De Fronzo RA, Chilton RJ. PROactive :time for a critical appraisal. Eur Heart J, 2008,29 :969 -983. 被引量：1
4Yamagishi S. Protective role of PPARgamma agonists against cardiovascular disease. Nippon Rinsho, 2010,68 :807-311. 被引量：1
5Tsuchiya K, Akaza I, Yoshimoto T, et al. Pioglitazone im- proves endothelial function with increased adiponectin and high density lipoprotein cholesterol levels in type 2 diabetes. Endocr J,2009,56:691-698. 被引量：1
6He L,Game BA, Nareika A, et al. Administration of pioglitazone in low-density lipoprotein receptor deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques. J Cardiovasc Pharmacol, 2006,48:212- 222. 被引量：1
7Takahashi A,Kushiro T. Pioglitazone effects on blood pres- sure in patients with metabolic syndrome. Nippon Rinsho, 2008,66:1591- 1595. 被引量：1
8Hettihewa LM, J ayasinghe SS, Imendra KG, et al. Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. Int J Diabetes Dev Ctries,2008,28:26 -30. 被引量：1
9Spanheimer R, Betteridge DJ,Tan MH, et al. Long term lipid effects of pioglitazone by baseline anti hyperglycemia medica- tion therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol,2009,104:234- 239. 被引量：1
10Terui G, Goto T, Katsuta M, et al. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type Ⅲ collagen in type 2 diabetic patients. J Cardiol,2009,54:52-58. 被引量：1

二级参考文献14

1Jason L,Kent A,Jennifer E,Van Eyk,Troponin I.Degradation and covalent complex formation accompanied myocardial ischemia/reperfusion injury[J] .Circ Res,1999;84:9-20 被引量：1
2Woodfield SL,Lundergan CF,Reiner JS,Greenhouse SW,Jhompson MA,Rohrbeck SC,et al.Angiographic findings and outcome in diabetic patiens treated with thrombolytic therapy for acute myocardial infarction: the GUATO-1 experience[J].J Am Coll Cardiol,1996;28:1661-9 被引量：1
3Murry CE,Ennings RB,Reimer KA.Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium[J].Circulation,1986;74:1124-36 被引量：1
4Chen L,Haug WH,Yang B,Saldeen TG,Parethasarathy S,Metha JL.Preservation of endogenous antioxidants activity and inhibition lipid peroxidation as common mechenism of antiatheroselerotic effect of vitamin E,lovastatin,and amlodipioc[J].J Am Coll Cardiol,1997;30: 569-75 被引量：1
5Wayman NS,Hattori Y,Mcdonald MC,Mota-Filipe H,Cuzaarea S,Pisano B,et al.Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size[J].FASEB J,2002;16: 1027-40 被引量：1
6Wang W,Schulze CJ,Suarez-Pinzon WL,Dyck JR,Sawichi G,Schulz R,et al.Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury[J].Circulation,2002;106:1543-9 被引量：1
7Tetsuga S,Hiroyuki T,Shunji H,Nobuhiro S,Masaki I,Jing W,et al.Pioglitazone,a peroxisome proliferator-activated receptor-γagonist,attenuate left ventricular remodling and failure after experimental myocardial infarction[J].Circulation,2002;106: 3126-32 被引量：1
8Thiemermann C,Zacharowski K.Selective activation of EP3 receptors reduces myocardial infarct size: a novel insight into the cardioprotective effects of prostaglandins[J].Pharmacol Ther,2000;87: 61-7 被引量：1
9Miura T,Imura O.Infarct size limitation by preconditioning:its phenomenological features and the key role of adenosine[J].Cardiovasc Res,1993;27: 36-42 被引量：1
10Vanden HT,Becker LB,Shao ZH,Li CQ,Schumacker PT.Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion[J].Circ Res,2000;86: 541-8 被引量：1